EGFR and non-small cell lung carcinoma: Interestingly, a recent study reported that EGFR-TKIs plus local therapy showed prolonged survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases, suggesting the good control effect of local therapy in patients with liver metastases.34 In view of the poor response of patients with liver metastasis to apatinib monotherapy, combination of apatinib and local consolidation strategies (e.g., radiotherapy and radiofrequency ablation) should be investigated for patients with SCLC and liver metastasis.